Cognition Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Cognition Therapeutics, Inc. (CGTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.00 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-26
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-06-30 was $1.54, a 1.91% decline year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.56, a 3.70% decline year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-09-30 was $1.25, a 14.97% decline year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.56, a 0.00% change from fiscal 2023.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.56, a 14.75% decline from fiscal 2022.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.83, a 79.87% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-26 | |||
| 2024-12-31 | $1.56 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $1.56 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $1.54 10-Q · filed 2025-08-07 | $1.56 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $1.56 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $1.56 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $1.25 10-Q · filed 2024-11-13 | $1.59 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $1.57 10-Q · filed 2024-08-08 | $1.61 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $1.62 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $1.83 10-K · filed 2024-03-26 | |||
| 2022-09-30 | $1.47 10-Q · filed 2023-11-02 | $1.90 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $2.00 10-Q · filed 2023-08-08 | $2.52 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $2.31 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $9.09 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $1.79 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $1.19 10-Q · filed 2022-08-09 | $1.39 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $1.39 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $0.97 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |